{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:05:20Z","timestamp":1789095920720,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The hydroxyurea is a save, affordable and essential medicine for sickle cell disease (SCD), reducing painful crises and mortality. To foster the prescription of hydroxyurea for patients with SCD in sub-Saharan African countries, the scientific advisory board of Drep.Afrique, a non-governmental organization dedicated to SCD in Africa, has developed a therapeutic guideline well suited to conditions on the ground. These guidelines answer three essential questions: which patients should be prioritized for treatment with hydroxyurea, which dose should be used, and what follow-up should be implemented in those low-resources countries?<\/jats:p>\n          <jats:p> The guidelines are given as in a concise document for easy use by practitioners on the ground, available in English and in French.<\/jats:p>","DOI":"10.1007\/s00277-024-06180-2","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:50:01Z","timestamp":1738788601000},"page":"937-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of hydroxyurea in French-speaking Sub-Saharan Africa"],"prefix":"10.1007","volume":"104","author":[{"given":"Jean-Beno\u00eet","family":"Arlet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bernaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indou","family":"Deme-Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binta","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Corbasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Diagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapa","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliou","family":"Diop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Eposse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Galacteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00e9onore","family":"Kafando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Lain\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"de Montalembert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constant","family":"Vodouh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahoefa","family":"Vovor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Ranque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9on","family":"Tshilolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"6180_CR1","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1016\/S2352-3026(23)00096-0","volume":"10","author":"FB Piel","year":"2023","unstructured":"Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA et al (2023) Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol 10:e633\u2013e686","journal-title":"Lancet Haematol"},{"key":"6180_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","volume":"380","author":"L Tshilolo","year":"2019","unstructured":"Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A et al (2019) Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med. 380:121\u2013131","journal-title":"N Engl J Med."},{"key":"6180_CR3","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1056\/NEJMoa2000146","volume":"382","author":"CC John","year":"2020","unstructured":"John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P et al (2020) Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med. 382:2524\u20132533","journal-title":"N Engl J Med."},{"issue":"24","key":"6180_CR4","first-page":"00078","volume":"S2352\u20133026","author":"B Aygun","year":"2024","unstructured":"Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN et al (2024) Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1\/2 trial. Lancet Haematol S2352\u20133026(24):00078\u201300084","journal-title":"Lancet Haematol"},{"key":"6180_CR5","unstructured":"https:\/\/www.afro.who.int\/publications\/who-sickle-package-interventions-sickle-cell-disease-managementDownloaded August 06, 2024."},{"issue":"Supplement 1","key":"6180_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/blood-2023-188652","volume":"142","author":"GK Keza","year":"2023","unstructured":"Keza GK, Diallo DA, Diagne I, de Montalembert M, Corbasson A, Bernaudin F et al (2023) Availability and cost of basic drugs for sickle cell disease in 13 African Countries. Blood. 142(Supplement 1):1152\u20131152","journal-title":"Blood."},{"key":"6180_CR7","unstructured":"https:\/\/ncdak.org\/wp-content\/uploads\/2021\/07\/NATIONAL-GUIDELINES-FOR-CONTROL-AND-MANAGEMENT-OF-SICKLE-CELL-DISEASE-IN-KENYA-.pdf Pages 16\u201317."},{"key":"6180_CR8","unstructured":"https:\/\/www.moh.go.tz\/storage\/app\/uploads\/public\/663\/c8f\/ceb\/663c8fceb418d132695047.pdf. Pages 65\u201366."},{"key":"6180_CR9","unstructured":"https:\/\/library.health.go.ug\/sites\/default\/files\/resources\/Uganda%20Clinical%20Guidelines%202023.pdf. Page 583."},{"key":"6180_CR10","unstructured":"https:\/\/sickle.nhm.gov.in\/uploads\/english\/OperationalGuidelines.pdf. Page 23."},{"key":"6180_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/MOH.0000000000000582","volume":"27","author":"A Power-Hays","year":"2020","unstructured":"Power-Hays A, Ware RE (2020) Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Curr Opin Hematol 27:172\u2013180","journal-title":"Curr Opin Hematol"},{"key":"6180_CR12","first-page":"505","volume":"73","author":"DA Diallo","year":"2023","unstructured":"Diallo DA, Habibi A, Arlet JB (2023) Improve education of physicians and other caregivers about sickle cell disease. Rev Prat 73:505\u2013508","journal-title":"Rev Prat"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06180-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:22:49Z","timestamp":1743888169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06180-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6180"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06180-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jean-Beno\u00eet Arlet declares the receipt of research funding from Addmedica\/Theravia, GBT-Pfizer, Novartis, and Vertex and speaker\u2019s fees from Novartis France and GBT. He co-founded the NGO Drep.Afrique.\u00a0Fran\u00e7oise Bernaudin declares the receipt of research funding from Pfizer, and receipt consulting fees BlueBirdBio and Pfizer; honoraria from Vertex and support for meetings from Addmedica and GBT.Anne Corbasson declares the receipt of speaker\u2019s fees for Pfizer and conference support from Vitalaire.\u00a0Saliou Diop declares the receipt of research funding from Addmedica\/Theravia, and honoraria from Novartis, Novo Nordisk, Pfizer, Octapharma and support for meetings from Novo Nordisk.Fr\u00e9d\u00e9ric Galact\u00e9ros declares the receipt honoraria and research funding from NOVARTIS, SANOFI, BLUEBIRDBIO, PFIZER, AGIOS, GBT, BMS, and ADDMEDICA Companies.Mariane de Montalembert is member of Advisory Boards for Novartis, Vertex, and Addmedica\/Theravia.Olivier Hermine declares the receipt of research funding from BMS, Roche, Alexion and support for travels from BMS.L\u00e9on Tshilolo declares the receipt of research funding from the NIHLB ; speaker\u2019s fees from Novartis, Novo Nordisk; honoraria from NIHLB and Drep.Afrique and support for meetings from the NIHLB, NNHL and Gate fondation.All other authors report no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}